CL2017002153A1 - Compuestos bicíclicos de sulfonamida cetona - Google Patents
Compuestos bicíclicos de sulfonamida cetonaInfo
- Publication number
- CL2017002153A1 CL2017002153A1 CL2017002153A CL2017002153A CL2017002153A1 CL 2017002153 A1 CL2017002153 A1 CL 2017002153A1 CL 2017002153 A CL2017002153 A CL 2017002153A CL 2017002153 A CL2017002153 A CL 2017002153A CL 2017002153 A1 CL2017002153 A1 CL 2017002153A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- ketone compounds
- present
- bicyclic sulfonamide
- bicyclic
- Prior art date
Links
- -1 Bicyclic sulfonamide ketone compounds Chemical class 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108010052164 Sodium Channels Proteins 0.000 abstract 2
- 102000018674 Sodium Channels Human genes 0.000 abstract 2
- 206010011224 Cough Diseases 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000007803 itching Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
<p>La presente invención proporciona compuestos de la Fórmula (I), en donde: como se define en la especificación, un enantiómero, diaestereómero, atropisómero del mismo, o una mezcla de los mismos, o sales farmacéuticamente aceptables de los mismos, que son inhibidores de los canales de sodio regulados por voltaje, en particular Nav 1.7. Los compuestos son útiles para el tratamiento de enfermedades que se tratan por la inhibición de canales de sodio tales como trastornos de dolor, tos, o comezón. También se proporcionan composiciones farmacéuticas que contienen los compuestos de la presente invención.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562127206P | 2015-03-02 | 2015-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002153A1 true CL2017002153A1 (es) | 2018-03-16 |
Family
ID=55543087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002153A CL2017002153A1 (es) | 2015-03-02 | 2017-08-24 | Compuestos bicíclicos de sulfonamida cetona |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10472356B2 (es) |
| EP (1) | EP3265465B1 (es) |
| JP (1) | JP6742331B2 (es) |
| KR (1) | KR102649836B1 (es) |
| CN (1) | CN107531705B (es) |
| AR (1) | AR103833A1 (es) |
| AU (1) | AU2016226340B2 (es) |
| BR (1) | BR112017018755B1 (es) |
| CA (1) | CA2978569C (es) |
| CL (1) | CL2017002153A1 (es) |
| CO (1) | CO2017009614A2 (es) |
| CR (1) | CR20170392A (es) |
| EA (1) | EA032928B1 (es) |
| ES (1) | ES2728759T3 (es) |
| HK (1) | HK1248687B (es) |
| IL (1) | IL254161B (es) |
| JO (1) | JO3595B1 (es) |
| MX (1) | MX374386B (es) |
| MY (1) | MY188700A (es) |
| NZ (1) | NZ734888A (es) |
| PE (1) | PE20180030A1 (es) |
| PH (1) | PH12017501570B1 (es) |
| SG (1) | SG11201707000UA (es) |
| TN (1) | TN2017000376A1 (es) |
| TW (1) | TWI700282B (es) |
| UA (1) | UA121671C2 (es) |
| UY (1) | UY36573A (es) |
| WO (1) | WO2016141035A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018175707A1 (en) | 2017-03-24 | 2018-09-27 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
| CN107991409B (zh) * | 2017-11-28 | 2020-04-24 | 中国医学科学院肿瘤医院 | 采用高效合相色谱同时测定血浆中12种磺胺类药物的方法 |
| WO2019191702A1 (en) * | 2018-03-30 | 2019-10-03 | F. Hoffmann-La Roche Ag | Substituted hydro-pyrido-azines as sodium channel inhibitors |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| WO2020199683A1 (zh) * | 2019-04-04 | 2020-10-08 | 上海海雁医药科技有限公司 | 氮杂环取代的磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
| JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
| JP7739051B2 (ja) | 2020-06-10 | 2025-09-16 | アムジエン・インコーポレーテツド | シクロブチルジヒドロキノリンスルホンアミド化合物 |
| US11319960B2 (en) * | 2020-09-03 | 2022-05-03 | Shenzhen Lanhe Technologies Co., Ltd. | Portable temperature regulation device |
| WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| AU2022283934A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| AU2022284952A1 (en) | 2021-06-04 | 2023-12-14 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| AU2022286438A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| MX2023014378A (es) | 2021-06-04 | 2023-12-15 | Vertex Pharma | N-(hidroxialquil(hetero)aril)tetrahidrofurano carboxamidas como moduladores de canales de sodio. |
| CN119522214A (zh) | 2022-04-22 | 2025-02-25 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的杂芳基化合物 |
| JP2025513452A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| KR20250005373A (ko) | 2022-04-22 | 2025-01-09 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료를 위한 헤테로아릴 화합물 |
| WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| AU2023391870A1 (en) | 2022-12-06 | 2025-06-05 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| TW202523313A (zh) | 2023-10-23 | 2025-06-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4620007A (en) * | 1980-09-03 | 1986-10-28 | Bayer Aktiengesellschaft | 6-fluoro-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid |
| KR20060118398A (ko) * | 2003-08-05 | 2006-11-23 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 이온 채널 억제제로서의 축합 피라미딘 화합물 |
| DE102004031850A1 (de) * | 2004-06-30 | 2006-01-26 | Sanofi-Aventis Deutschland Gmbh | Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
| WO2006106423A2 (en) * | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
| EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| WO2011103715A1 (en) * | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| JP2014532660A (ja) * | 2011-10-28 | 2014-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおける選択活性を有するベンゾオキサゾリノン化合物 |
| US9346798B2 (en) | 2012-02-13 | 2016-05-24 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
| WO2014201173A1 (en) * | 2013-06-12 | 2014-12-18 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
-
2016
- 2016-03-02 CR CR20170392A patent/CR20170392A/es unknown
- 2016-03-02 EA EA201791941A patent/EA032928B1/ru not_active IP Right Cessation
- 2016-03-02 MX MX2017011042A patent/MX374386B/es active IP Right Grant
- 2016-03-02 PE PE2017001464A patent/PE20180030A1/es unknown
- 2016-03-02 AR ARP160100551A patent/AR103833A1/es active IP Right Grant
- 2016-03-02 SG SG11201707000UA patent/SG11201707000UA/en unknown
- 2016-03-02 CA CA2978569A patent/CA2978569C/en active Active
- 2016-03-02 TN TNP/2017/000376A patent/TN2017000376A1/en unknown
- 2016-03-02 BR BR112017018755-8A patent/BR112017018755B1/pt active IP Right Grant
- 2016-03-02 UY UY0001036573A patent/UY36573A/es active IP Right Grant
- 2016-03-02 MY MYPI2017001273A patent/MY188700A/en unknown
- 2016-03-02 KR KR1020177027941A patent/KR102649836B1/ko active Active
- 2016-03-02 CN CN201680024836.2A patent/CN107531705B/zh active Active
- 2016-03-02 UA UAA201709532A patent/UA121671C2/uk unknown
- 2016-03-02 US US15/554,801 patent/US10472356B2/en active Active
- 2016-03-02 ES ES16710566T patent/ES2728759T3/es active Active
- 2016-03-02 JP JP2017546195A patent/JP6742331B2/ja active Active
- 2016-03-02 JO JOP/2016/0032A patent/JO3595B1/ar active
- 2016-03-02 EP EP16710566.7A patent/EP3265465B1/en active Active
- 2016-03-02 NZ NZ734888A patent/NZ734888A/en unknown
- 2016-03-02 HK HK18108233.0A patent/HK1248687B/en unknown
- 2016-03-02 TW TW105106422A patent/TWI700282B/zh active
- 2016-03-02 AU AU2016226340A patent/AU2016226340B2/en active Active
- 2016-03-02 WO PCT/US2016/020403 patent/WO2016141035A1/en not_active Ceased
-
2017
- 2017-08-24 CL CL2017002153A patent/CL2017002153A1/es unknown
- 2017-08-27 IL IL254161A patent/IL254161B/en active IP Right Grant
- 2017-08-31 PH PH12017501570A patent/PH12017501570B1/en unknown
- 2017-09-22 CO CONC2017/0009614A patent/CO2017009614A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002153A1 (es) | Compuestos bicíclicos de sulfonamida cetona | |
| UY35612A (es) | Compuestos de sulfonamida bicíclicos como inhibidores de los canales de sodio | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
| JOP20180113B1 (ar) | مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| UY37205A (es) | Inhibidores de bromodominios | |
| GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
| DOP2014000265A (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
| CO2018007436A2 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| EA201791327A1 (ru) | Композиции 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| AR104731A1 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
| CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| MX378012B (es) | Compuestos de alquinil dihidroquinolina sulfonamida. | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
| MX2018004868A (es) | Derivados de la pirrolidina. | |
| UY36123A (es) | Derivados de carboxamida | |
| EA201792594A1 (ru) | Положительные аллостерические модуляторы мусаринового рецептора м1 | |
| CO2020001375A2 (es) | Derivado de adamantilmetilamina y uso del mismo como producto farmacéutico | |
| CL2020001089A1 (es) | Compuestos inhibidores de tirosina cinasa de bruton (btk). | |
| AR111416A2 (es) | Compuesto terapéutico para el dolor y síntesis del compuesto | |
| EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam | |
| CU20140134A7 (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa |